Ambrx Biopharma, Inc.
AMAMDelisted Mar 7, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001990550
Ambrx Biopharma, Inc. was delisted on Mar 7, 2024; its insiders filed their last Form 4 on Mar 7, 2024; 68 institutions reported holding it in 13F filings for Q4 2023, worth $912.7M in total; no superinvestor held it.
13F holders, Q1 2022
Institutional positions in Ambrx Biopharma, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −2 vs. Q4 2021
- Shares held
- 17.1M
- +306.3K (+1.8%) vs. Q4 2021
- Total value
- $70.6M
- −$81.4M (−53.5%) vs. Q4 2021
- New holders
- 0
- 5 more added
- Sold out
- 2
- 3 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting AMAM on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 68 | $912.7M |
| Q3 2023 | 44 | $568.3M |
| Q2 2023 | 42 | $788.8M |
| Q1 2023 | 30 | $330.7M |
| Q4 2022 | 18 | $40.7M |
| Q3 2022 | 16 | $18.0M |
| Q2 2022 | 14 | $45.4M |
| Q1 2022 | 14 | $70.6M |
| Q4 2021 | 16 | $152.0M |
| Q3 2021 | 15 | $165.3M |
| Q2 2021 | 20 | $266.2M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Ambrx Biopharma, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 241 | $1.00K | 0.00% | +110+84.0% | Added |
| Morgan Stanley | 2,800 | $12.0K | 0.00% | 00.0% | Unchanged |
| Tudor Investment Corp Et Al | 20,143 | $83.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 22,600 | $93.0K | 0.00% | +10,800+91.5% | Added |
| Norges Bank | 70,000 | $288.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 104,429 | $430.0K | 0.00% | +6,010+6.1% | Added |
| Octagon Capital Advisors LP | 149,400 | $616.0K | 0.13% | −187,468−55.7% | Reduced |
| Suvretta Capital Management, LLC | 1,491,832 | $6.15M | 0.19% | +434,097+41.0% | Added |
| Fosun International Ltd | 1,932,591 | $7.96M | 0.69% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 2,027,291 | $8.35M | 0.02% | +103,591+5.4% | Added |
| Artal Group S.A. | 2,152,291 | $8.87M | 0.37% | 00.0% | Unchanged |
| Cormorant Asset Management, LP | 2,486,386 | $10.2M | 0.79% | 00.0% | Unchanged |
| BlackRock Inc. | 2,851,486 | $11.7M | 0.00% | −18,000−0.6% | Reduced |
| FMR LLC | 3,825,359 | $15.8M | 0.00% | −29,666−0.8% | Reduced |
| Caas Capital Management LP | 0 | $0 | 0.00% | −13,068−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −124−100.0% | Sold out |